Astellas Pharma Inc. and Iveric bio, Inc. have entered into a definitive agreement under which Astellas through Berry Merger Sub, Inc., a wholly-owned subsidiary of Astellas US Holding, Inc., has agreed to acquire Iveric Bio for a total equity value of approximately $5.9 billion.
 
The acquisition provides a foundation of ophthalmology focused capabilities, including a commercial team, expansive network of experts in the ophthalmology field, established relationships with medical institutions, and the infrastructure to drive the combined ophthalmology business going forward. Through acquired capabilities, Astellas will accelerate preclinical and clinical development and commercialization activities to contribute to the goals of Primary Focus, “Blindness & Regeneration.”
 
Iveric Bio will become an indirectly wholly-owned subsidiary of Astellas. The Boards of Directors of both companies have unanimously approved the transaction.